Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aristolochic acid

This article was originally published in The Tan Sheet

Executive Summary

Thirteen Treasure of the East products containing herb linked to kidney failure and increased cancer risk recalled by Ithaca, N.Y.-based Blue Light, FDA announces June 20. Total of 1,213 bottles of powder or capsules distributed nationwide, mainly to specialty retailers and herbal practitioners; no illnesses have been reported, agency notes. FDA Acting Principle Deputy Director Bernard Schwetz, PhD, recently asked health professionals to assist in cataloging renal adverse events possibly related to ingestion of frequently recalled herb (1"The Tan Sheet" June 11, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel